Eriksen JG, Maare C, Johansen J, Primdahl H, et al. DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck. Radiother Oncol 2025 Apr 19:110899. doi: 10.1016/j.radonc.2025.110899.
PMID: 40258418